| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.22 | 3e-05 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.15 | 3e-05 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.15 | 4e-05 |
| mRNA | embelin | GDSC1000 | pan-cancer | AAC | -0.15 | 9e-05 |
| mRNA | 3-Cl-AHPC | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0001 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.2 | 0.0005 |
| mRNA | AZD7762 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0005 |
| mRNA | pitstop2 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.0008 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |